Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.

PloS one - 1 Jan 2015

Wang Jingxuan, Lu Kangping, Song Ying, Zhao Shu, Ma Wenjie, Xuan Qijia, Tang Dabei, Zhao Hong, Liu Lei, Zhang Qingyuan

Abstract excerpt

BACKGROUND: Breast cancer patients treated with aromatase inhibitors (AIs) may experience musculoskeletal adverse events (MS-AEs). Several studies have confirmed that the RANKL/RANK/OPG signaling pathway plays a dominant role in bone health. Therefore, this study aimed to analyze the relationship between the serum levels of RANKL, OPG and their SNPs (single nucleotide polymorphisms) with AI-related MS-AEs....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aromatase Inhibitors
Share to Asian People

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Follow-Up Studies

Share to Musculoskeletal Diseases

Share to Neoplasm Grading

Share to Osteoprotegerin

Share to RANK Ligand

Source

Open in PubMed Open full text

Identifiers

PMID: 26218592
DOI: 10.1371/journal.pone.0133964
PMCID: PMC4547828

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.PMID 26218592Read ↗

Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.Semantic proximity Read ↗

Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer.Semantic proximity Read ↗

Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.Semantic proximity Read ↗

Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.Semantic proximity Read ↗

The association between RANKL and Osteoprotegerin gene polymorphisms with breast cancer.Semantic proximity Read ↗

ESR1 polymorphisms were associated with aromatase inhibitors induced musculoskeletal symptoms in breast cancer patients.Semantic proximity Read ↗

Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.Semantic proximity Read ↗

Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations.Semantic proximity Read ↗

Genetic polymorphism of the OPG gene associated with breast cancer.Semantic proximity Read ↗

Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.Semantic proximity Read ↗

Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm.Semantic proximity Read ↗

Polymorphisms in the RANK/RANKL genes and their effect on bone specific prognosis in breast cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.